Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin BI 907828 treatment in patients with treatment-na�ve or pre-treated advanced dedifferentiated liposarcoma

Brief Summary

Type:
Sarcomas

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06058793

Study #:
STUDY00160228

Start Date:
Apr 21, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06058793

View Complete Trial Details & Eligibility at ClinicalTrials.gov